LSE •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/24/2026 16:35
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeLSE
Market Capitalization1,345.51 mln
Float508 mln
Earnings Date08/07/2026
EPS
40.00
Exceptional
P / E
4.00
Deeply undervalued
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.24
Manipulation likely
1-Year Forecast
352
Transformational upside
Relative Strength
12
/ 100
Significantly lagging
Business Description
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company founded in 2000 that researches and brings to market treatments for cancer and immune system disorders across global markets. The company has built a broad portfolio of drug candidates targeting various cancers, including colorectal, lung, gastric, and blood cancers, as well as conditions like immune thrombocytopenic purpura. Several of its medicines are already approved and available to patients, while others are progressing through clinical trials. HUTCHMED works alongside major pharmaceutical partners including AstraZeneca, Lilly, and Takeda to advance its pipeline.
